Zoladex 10.8mg depot (every 12 weeks) is non-inferior to Zoladex 3.6mg depot (every 4 weeks) in terms of oestradiol (E2) suppression in patient population by assessment of area under the curve of E2 concentration during the first 24 weeks of treatment. every 12 weeks [clinicaltrials_resource:b85069a64c4f5851091b4eea8346019a]
Zoladex 3-month depot
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Zoladex 10.8mg depot (every 12 weeks) is non-inferior to Zoladex 3.6mg depot (every 4 weeks) in terms of oestradiol (E2) suppression in patient population by assessment of area under the curve of E2 concentration during the first 24 weeks of treatment. every 12 weeks [clinicaltrials_resource:b85069a64c4f5851091b4eea8346019a]
Zoladex 3-month depot
Bio2RDF identifier
b85069a64c4f5851091b4eea8346019a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:b85069a64c4f5851091b4eea8346019a
measure [clinicaltrials_vocabulary:measure]
Zoladex 10.8mg depot (every 12 ...... e first 24 weeks of treatment.
time frame [clinicaltrials_vocabulary:time-frame]
every 12 weeks
description
Zoladex 3-month depot
identifier
clinicaltrials_resource:b85069a64c4f5851091b4eea8346019a
title
Zoladex 10.8mg depot (every 12 ...... s of treatment. every 12 weeks
@en
type
label
Zoladex 10.8mg depot (every 12 ...... 069a64c4f5851091b4eea8346019a]
@en